Cardiovascular medications in angiogenesis—How to avoid the sting in the tail

Authors

  • Chenming Ma,

    1. Research Group Surgical Oncology, Experimental and Clinical Research Center, Max Delbrueck Center and Charité Campus Buch, Berlin, Germany
    Search for more papers by this author
    • C. Ma and Q. Wang contributed equally to this article.

  • Qing Wang,

    1. Research Group Surgical Oncology, Experimental and Clinical Research Center, Max Delbrueck Center and Charité Campus Buch, Berlin, Germany
    Search for more papers by this author
    • C. Ma and Q. Wang contributed equally to this article.

  • Yicun Man,

    1. Research Group Surgical Oncology, Experimental and Clinical Research Center, Max Delbrueck Center and Charité Campus Buch, Berlin, Germany
    Search for more papers by this author
  • Wolfgang Kemmner

    Corresponding author
    1. Research Group Surgical Oncology, Experimental and Clinical Research Center, Max Delbrueck Center and Charité Campus Buch, Berlin, Germany
    • Research Group Surgical Oncology, Experimental Clinical Research Center at the Max-Delbrueck-Center for Molecular Medicine, Charité Campus Buch, Lindenbergerweg 80, Berlin 13125, Germany
    Search for more papers by this author
    • Tel.: +49-30-9406-2506, Fax: +49-30-9406-2846


Abstract

Cancer and cardiovascular disease are the leading causes of death worldwide. Cardiovascular medications have recently been found to have favorable effects also for the treatment of noncardiovascular diseases, including cancer. In this review, we use a reverse bedside-to-bench approach to investigate the effects of common cardiovascular medications on tumor angiogenesis and vascular angiogenesis. Aspirin seems to reduce the risk of developing cancer, particularly colon cancer. However, whether the protective influence of aspirin is due to antiangiogenesis effect is still unclear. β-Blockers, which are normally used to reduce heart rate and prolong diastole, trigger an increase in stretch-associated release of proangiogenic growth factors thereby inducing angiogenesis. However, according to other studies β-blockers are able to inhibit angiogenesis via multiplicate mechanisms. Similarly, angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor blocker have controversial effects for the regulation of cell proliferation and angiogenesis. Statins can augment collateral vascular growth in ischemic tissues and restrict the development of cancer. So this topical anti-inflammatory drug seems to be of high value for further therapy. Finally, suggestions on how this pilot experience may guide the conduct of future preclinical investigations, and clinical trials are discussed.

Ancillary